NCT06127966

Brief Summary

This study aims to investigate whether preoperative NLR (Neutrophil-to-Lymphocyte Ratio) serves as a biomarker for PONV (Postoperative Nausea and Vomiting). It also examines the impact of erector spinae plane block on NLR and PONV. Furthermore, the research explores the effect of erector spinae plane block on postoperative pain relief in spinal surgery and its influence on the usage of opioid medications.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
220

participants targeted

Target at P75+ for phase_1

Timeline
4mo left

Started Aug 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Aug 2025Sep 2026

First Submitted

Initial submission to the registry

October 29, 2023

Completed
15 days until next milestone

First Posted

Study publicly available on registry

November 13, 2023

Completed
1.7 years until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

July 29, 2025

Status Verified

July 1, 2025

Enrollment Period

1 year

First QC Date

October 29, 2023

Last Update Submit

July 24, 2025

Conditions

Keywords

Neutrophil to Lymphocyte RatioPostoperative Nausea and Vomitingerector spinae plane blockPostoperative analgesialumbosacral spine surgery

Outcome Measures

Primary Outcomes (3)

  • Record nausea and vomiting within the PACU and during the first 24 hours and second 24 hours after surgery.

    Patients with a nausea and vomiting score of 1 point or above (0 points = no nausea, 1 point = nausea, 2 points = dry heaving, 3 points = vomiting) are treated with ondansetron as an antiemetic.

    Within the first 24 hours and the second 24 hours after surgery.

  • Record the need for antiemetic medication within the PACU and during the first 24 hours and the second 24 hours postoperatively.

    Record the need for antiemetic medication within the PACU and during the first 24 hours and the second 24 hours postoperatively.

    Within the first 24 hours and the second 24 hours after surgery.

  • Record the neutrophil count and lymphocyte count on the first day after surgery and calculate the neutrophil-to-lymphocyte ratio (NLR)

    The neutrophil count and lymphocyte count and calculate the neutrophil-to-lymphocyte ratio (NLR).

    Within the first 24 hours.

Secondary Outcomes (10)

  • Overall VAS (Visual Analog Scale) pain scores at 2 hours, 6 hours, 12 hours, 24 hours, and 48 hours postoperatively during rest and movement.

    At 2 hours, 6 hours, 12 hours, 24 hours, and 48 hours after surgery

  • Record the time of the patient's initial self-administration of the pain pump during the first 24 hours and the second 24 hours after surgery.

    Within the first 24 hours and the second 24 hours after surgery

  • Record the time of the initial press of the patient-controlled analgesia pump.

    Within the first 24 hours and the second 24 hours after surgery

  • Record the satisfaction scores for pain management at 24 and 48 hours.

    Within the first 24 hours and the second 24 hours after surgery

  • Record the postoperative awakening time.

    Within 24 hours.

  • +5 more secondary outcomes

Study Arms (2)

Erector Spinae Plane Block group(EA group + EB group)

EXPERIMENTAL

Conventional anesthesia induction, followed by ultrasound-guided erector spinae plane (ESPB) block with 0.5% ropivacaine (20 ml) after anesthesia induction.

Procedure: Erector Spinae Plane Block

Control group(CA group + CB group)

SHAM COMPARATOR

Conventional anesthesia induction, followed by ultrasound-guided injection of 0.9% saline (20 ml) into the erector spinae plane (ESPB) after anesthesia induction.

Procedure: 0.9% physiological saline (20ml) injection under ultrasound-guided Erector Spinae Plane Block (ESPB).

Interventions

The patient assumes a prone position, and the appropriate lumbar vertebral level is identified using ultrasound, based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is placed in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process and the overlying erector spinae and latissimus dorsi muscles. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process and there is no blood or gas upon aspiration, 2-3 mL of isotonic saline solution is injected to confirm the correct needle position. Local anesthetic is then injected between the erector spinae muscle and the transverse process. The spread of the local anesthetic in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.

Erector Spinae Plane Block group(EA group + EB group)

The patient is placed in a prone position, and the appropriate lumbar vertebral level is determined using ultrasound based on the preoperative markings of the surgical incision site. After disinfection, the ultrasound probe is positioned in the parasagittal direction, 3 centimeters lateral to the midline, to identify the corresponding lumbar transverse process, erector spinae, and latissimus dorsi muscles above it. Using an in-plane technique, the needle is advanced, and when the needle tip contacts the bony transverse process, and there is no blood or gas upon aspiration, 2-3 milliliters of isotonic saline solution are injected to confirm the correct needle position. Subsequently, 20 milliliters of 0.9% physiological saline is injected between the erector spinae muscle and the transverse process. The diffusion of the physiological saline in the deep fascial plane within the erector spinae muscle can be visualized using ultrasound.

Control group(CA group + CB group)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing elective posterior lumbar spine surgery in a prone position under general anesthesia.
  • ASA classification grades I to II.
  • Age between 18 and 80 years old.
  • Signed the informed consent for this study.

You may not qualify if:

  • Preoperative blood transfusion.
  • Uncontrolled systemic diseases.
  • Patients with known uncontrolled systemic inflammatory diseases (e.g., rheumatoid arthritis, lupus, or active infections).
  • Gastrointestinal system disorders.
  • History of antiemetic and anticholinergic drug use.
  • History of adverse reactions related to surgery, deformity correction surgeries, defined as procedures involving instrumentation across three or more levels or aimed at correcting scoliosis or kyphosis.
  • Severe spinal deformities.
  • Infection at the puncture site.
  • Coagulation disorders.
  • Long-term use of sedatives and analgesic drugs before surgery.
  • Patients with mental illness or communication barriers.
  • Allergic to ropivacaine.
  • Participants involved in other clinical studies within the past 3 months.
  • History of previous lumbar surgeries.
  • Subjective unwillingness to participate in this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Wang JJ, Wang Y, Li XF, Chen SS, Wang Y, Sun PY, Yang HK, Shi P, Wu G. The impact of erector spinae plane block on neutrophil-to-lymphocyte ratio and postoperative nausea and vomiting in lumbar spine surgery patients: a protocol for a randomized controlled trial. Front Med (Lausanne). 2025 Aug 28;12:1630821. doi: 10.3389/fmed.2025.1630821. eCollection 2025.

MeSH Terms

Conditions

Postoperative Nausea and Vomiting

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsNauseaSigns and Symptoms, DigestiveSigns and SymptomsVomiting

Central Study Contacts

Guanghan Wu, Attending physician

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending physician

Study Record Dates

First Submitted

October 29, 2023

First Posted

November 13, 2023

Study Start

August 1, 2025

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

July 29, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share